Companies/CorMedix Inc.

Company profile

CorMedix Inc.

NASDAQ: CRMD · Healthcare · Biotechnology

PublicHQ Berkeley Heights, NJCIK 0001410098Reports USD

#241 of 1,394 Healthcare companies by revenuetop-decile growth

EA Score

75B+

FH 84DQ 67GM 65SS 67

v0.1 · 65/100 weight · provisional

↑ operating margin, 3-yr revenue growth · ↓ growth stability, filing timeliness

Methodology →

Revenue TTM

$400.1M

Rev growth YoY (TTM)

+384.6%

Net income (FY)

$163.1M

Employees

Market cap

$686.5M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$311.7M$311.7M2025

Net income$163.1M$163.1M2025

Operating income$150.1M$150.1M2025

Total assets$826.1M$826.1M2025

Liabilities$420.8M$420.8M2025

Equity$405.3M$405.3M2025

Revenue trend

FY2017 – FY2025 · USD

$329.3k

FY17

$429.8k

FY18

$283.3k

FY19

$239.2k

FY20

$190.9k

FY21

$65.4k

FY22

$43.5M

FY24

$311.7M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Product100%

By geography

Not disclosed.

The read

CorMedix Inc. booked $311.7M in FY2025 revenue, growing 617% year over year — faster than 95% of Healthcare companies we track, at a 52.3% net margin.

Peers · Healthcare

REGENXBIO Inc.54D ProKidney Corp.41D 4D Molecular Therapeutics, Inc.58C Ginkgo Bioworks Holdings, Inc.44D

Key facts

CEOJoseph Todisco

SectorHealthcare

IndustryBiotechnology

HeadquartersBerkeley Heights, NJ

ExchangeNASDAQ: CRMD

Employees64

IPO date2010-05-13

Latest filings

8-K2026-07-02 8-K2026-07-01 8-K2026-06-24 8-K2026-06-08 10-Q2026-05-14 8-K2026-05-14 DEF 14A2026-04-29 8-K2026-04-27

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.